Abstracts

Characterizing Novel N-Terminal Domains of APOBEC3G

Background: The human cytidine deaminase APOBEC3G (A3G) has been shown to exhibit antiviral function in the absence of its established catalytic function. A thorough molecular understanding of this deamination-independent mechanism is largely unknown. Methodology: We sought out to characterize the A3G protein and identify key regions and domains related to its antiviral function. A library…

Natural Resistance to HIV-1 by Select APOBEC3H Haplotypes

Background: HIV-1 pathogenesis requires neutralization of innate immune defenses. For instance, its viral infectivity factor (Vif) triggers the degradation of several members of the APOBEC3 family of DNA cytosine deaminases. Without Vif, HIV-1 succumbs to lethal mutagenesis inflicted by APOBEC3D, F, G, and H. Overexpression studies have shown that polymorphisms in human APOBEC3H encode proteins…

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated during Acute HIV Infection

Background: Enhancing HIV-1 specific immunity without CD4 T cell activation may clear productively infected cells, a key aspect of eradication strategies. We assessed the safety and immunogenicity of AGS-004 dendritic cell (DC) therapy in patients initiating ART during acute HIV infection (AHI). Methodology: In an open-label, single arm sub-study of AGS-004-003, DC therapy was administered…

Immunogenicity and VL Rebound After ATI in Chronic HIV Infected Patients Receiving MVA-B

Background: Poxvirus-based vaccines have shown great potential as HIV vaccines. We present the safety and immunogenicity results of a phase I, double blinded, placebo-controlled therapeutical vaccine trial of an MVA vector expressing HIV-1 antigens from clade B (MVA-B) in successfully cART-treated HIVinfected patients who underwent cART interruption. Methodology: Patients were randomly allocated to receive 3…

Dynamics of VL Rebound After cART Interruption in HIV Patients Receiving MVA-B Plus Disulfiram

Background: In vitro data suggest that stimulation of HIV-1-specific T lymphocytes with a therapeutic vaccine could facilitate elimination of latent viral reservoir after virus reactivation with drugs (i.e disulfiram). We present the results of a substudy of a phase I, doubled blind placebo-controlled trial of an MVA-B therapeutic trial combined with disulfiram virus-reactivation treatment in…

Immune Function and Viral Load Post AGS-004 Administration to Chronic HIV*Subjects Undergoing STI

Background: HIV infection induces immune dysregulation of both CD4 and CD8 T cell compartments. The anti-viral T cell pools in chronically infected patients are characterized by an exhausted activation phenotype, which is unable to control virus replication. ART can suppress HIV replication leading to stabilizing of CD4 T cell numbers and improving immune function. However,…

Impact of Early ART on HIV Eradication in Children

Background: Combination antiretroviral therapy (cART) initiated within three months of birth is not only effective in controlling HIV-1 replication and preserving immune function but also markedly reduces HIV-1 related mortality. Early diagnosis of HIV-1 infected infants and initiation of cART is thus recommended globally. The development of highly sensitive assays has facilitated the characterization of…

T Memory Stem Cells: The Stem Cell Reservoir for HIV?

Background: Current antiretroviral combination therapy is extremely effective in suppressing HIV-1 viremia but replication-competent HIV-1 can persist for extremely long-periods of time despite effective treatment with HAART. Defining the cell types that serve as a reservoir for long-term persistence of HIV-1 is critical for designing interventions that may at one point lead to HIV-1 eradication…

Inflammation as an Obstacle for Remission: Lessons Learned From Non-Human Primate Models

Background: Chronic immune activation (IA) during HIV-1 infection persists even in patients with controlled viremia. This residual inflammation might fuel viral replication by creating new target cells and thus could represent an additional obstacle for cure. Early treatment likely has a favourable impact on the reduction of viral reservoirs, and eventually on the inflammatory set…